secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-08-03T20:15:23+00:00
Accession:  0001837607-26-000057
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma regains NYSE American listing compliance after $13.6M offering
-----------------------------------------------------------------------------

- Received NYSE American letter confirming compliance with continued listing standards; .BC indicator to be removed.
- Resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
- Compliance achieved after July 2026 underwritten public offering: 17.85M shares + pre-funded warrants, net proceeds ~$13.6M.
- Potential additional $34M gross proceeds from milestone warrants if fully exercised.
- Company believes stockholders' equity now exceeds $4M minimum requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/0001837607-26-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/aeon-20260803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer